

6. Literaturverzeichnis

1. Albert F.
Tumorblutungen bei intrakraniellen Geschwülsten.
Neurochirurgica 1986;29:67-74.
2. Albert FK, Forsting M, Sartor K, et al.
Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis.
Neurosurgery 1994;34(1):45-60.
3. Alvord EC Jr.
Is necrosis helpful in the grading of gliomas? Editorial opinion.
J Neuropathol Exp Neurol 1992;51:127-32.
4. Annegers JF, Schoenberg BS, Okazaki H, et al.
Epidemiologic study of primary intracranial neoplasms.
Arch Neurol 1981;38:217-9.
5. Awwad S, Cull A, Gregor A.
Long-term survival in adult hemispheric glioma: prognostic factors and quality of outcome.
Clin Oncol R Coll Radiol 1990;2:343-6.
6. Bahemuka M.
Worldwide incidence of primary CNS neoplasms.
Brain 1988;111:737-53.
7. Bailey OT.
Genesis of the Percival Bailey-Cushing classification of gliomas.
Pediatr Neurosci 1985-86;12:261-5.
8. Bailey P, Cushing H.
A Classification of the Tumors of the Glioma Group on a Histogenetic Basis
With a Correlated Study of Prognosis.
Philadelphia Lippincott, 1926.
9. Bamberg M.
Zentralnervensystem.
In: Dold U, Hermanek P, Höffken K, Sack H, Hrsg.
Praktische Tumorthherapie maligner Organtumoren und Systemerkrankungen.
Stuttgart Thieme, 1993:71-3.

10. Bamberg M, Hess CF.
Radiation therapy of malignant gliomas.
Onkologie 1992;15:178-89.
11. Barker FG 2nd, Chang SM, Gutin PH, et al.
Survival and functional status after resection of recurrent glioblastoma multiforme.
Neurosurgery 1998;42(4):709-20.
12. Barker FG 2nd, Chang SM, Huhn SL, et al.
Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentoriell cerebral tumors.
Cancer 1997;80(5):936-41.
13. Barker FG, Davis RL, Chang SM, et al.
Necrosis as a prognostic factor in glioblastoma multiforme.
Cancer 1996;77:1161-6.
14. Batchelor TT, Betensky RA, Esposito JM, et al.
Age-dependent prognostic effects of genetic alterations in glioblastoma.
Clin Cancer Res 2004;10:228-33.
15. Batzdorf U, Malamud N.
The problem of multicentric gliomas.
J Neurosurg 1963;20:122-36.
16. Bendszus M, Warmuth-Metz M, Klein R, et al.
MR spectroscopy in gliomatosis cerebri.
AJNR 2000;21:375-80.
17. Bennett AH, Godlee RJ.
Case of cerebral tumour: The surgical treatment.
Trans R Med Chir Soc Lond 1885;68:243-75.
18. Bigner SH, Mark J, Bigner DD.
Cytogenetics of human brain tumors.
Cancer Genet Cytogenet 1990;47(2):141-54.
19. Bigner SH, Mark J, Burger PC, et al.
Specific chromosomal abnormalities in malignant human gliomas.
Cancer Res 1988;48(2):405-11.

20. Bigner SH, Mark J, Mahaley MS et al.
Patterns of the early, gross chromosomal changes in malignant human gliomas.
Hereditas 1984;101(1):103-13.
21. Bindal AK, Hammoud M, Ming Shi W, et al.
Prognostic significance of proteolytic enzymes in human brain tumors.
J Neuro Oncol 1994;22:101-10.
22. Bird CR, Drayer BP, Medina M, et al.
Gd-DPTA-enhanced MR imaging in pediatric patients after brain tumor resection.
Radiology 1988;169:123-6.
23. Black KL, Hawkins RA, Kim KT, et al.
Use of thallium-201 SPECT to quantitate malignancy grade of gliomas.
J Neurosurg 1989;71:342.
24. Bleehen NM, Stenning SP.
A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma-the Medical Research Council Brain Tumour Working Party.
BrJCancer 1991;64:769-74.
25. Bondy ML, Wrensch M.
Update on brain cancer epidemiology.
Bull Cancer 1993;45:365-9.
26. Bonner K, Siegel KR.
Pathology, treatment and management of posterior fossa brain tumors in childhood.
J Neurosci Nurs 1988;20(2):84-93.
27. Boyko OB.
Adult brain tumors.
In: Stark DD, Bradley WG Jr, eds. Magnetic resonance imaging. 3rd ed.
St.Louis Mosby-Year Book, 1999:1231-49.
28. Brem H, Piantadosi S, Burger PC, et al.
Placebo-controlled trial of safety and efficiency of intraoperative controlled Delivery by biodegradable polymers of chemotherapy for recurrent gliomas.
Lancet 1995;345:1008-12.

29. Brenner DJ, Martel MK, Hall EJ.
Fractionated regimens for stereotactic radiotherapy of recurrent tumors in the brain.
Int J Radiat Oncol Biol Phys 1992;21:819-24.
30. Bressler H.
Die Krankheiten des Gehirns und der äußeren Kopfbedeckungen.
Berlin, 1839.
31. Brock PD, Bower M.
Current perspectives in gliomas.
Med Oncol 1997;14:103-20.
32. Brody AS.
New perspectives in CT and MR imaging.
Neurol Clin 1991;9(2):273-86.
33. Buchpiguel CA, Alavi JB, Kenyon LC.
PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain.
J Nucl Med 1995;36:159.
34. Burger PC, Heinz ER, Shibata T, et al.
Topographic anatomy and CT correlation`s in the untreated glioblastoma multiforme.
J Neurosurg 1988;68:698-704.
35. Burger PC, Vogel FS, Green SB, et al.
Glioblastoma multiforme and anaplastic astrocytoma.
Cancer 1985;56:1106-11.
36. Burger PG, Green SB.
Patient age, histological features and length of survival in patients with glioblastoma multiforme.
Cancer 1987;59:1617-25.
37. Chamberlin MC, Murovic JA, Levin VA.
Absence of contrast enhancement after contrastinjection.
In: Caillé JM, Salomon G, eds. Computerized Tomography.
Berlin Springer, 1988:166-71.

38. Curran WJ, Scott CB, Horton J.
Recursive partitioning analysis of prognostic factors in three Radiation Therapy oncology Group malignant glioma trials.
J Natl Cancer Inst 1993;85:704-10.
39. Davis LE.
Presidential address: Malignant glioma - a nemesis which requires clinical and basic investigation in radiation oncology.
Int J Radiat Oncol Biol Phys 1989;16:1355-65.
40. Di Chiro G.
Positron emission tomography using [¹⁸F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool.
Invest Radiol 1987;22(5):360-71.
41. DiChiro G, Oldfield E, Wright DC, et al.
Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathological studies.
AJR 1988;150:189-97.
42. Emami B, Lyman J, Brown A, et al.
Tolerance of normal tissue to therapeutic irradiation.
Int J Radiat Oncol Biol Phys 1991;21(1):109-22.
43. Engenhardt-Cabillic R.
Therapiekonzepte bei primären und sekundären Hirntumoren.
In: Böttcher HD, Seifert V, Henke M, Hrsg.
Klinik der hirneigenen Tumoren und Metastasen.
München Zuckschwerdt, 2002:128-38.
44. Fadul C, Wood J, Thaler H, et al.
Morbidity and mortality of craniotomy for excision of supratentorial gliomas.
J Neurosurg 1988;38:1374-9.
45. Franklin CI.
Does extent of surgery make a difference in high grade malignant glioma?
Australas Radiol 1992;36:44-7.
46. Friedman HS, McLendon RE, Kerby T, et al.
DNA mismatch repair and O⁶-alkylguanine-DANN alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
J Clin Oncol 1998;16:3851-7.

47. Fritz P, Becker F, Kuttig H, et al.
Ergebnisse der lokalen Strahlentherapie und modifizierten Ganzhirnbestrahlung von Astrozytomen.
Strahlenther Onkol 1989;165:571-7.
48. Galanski M, Peters PE.
Hirnschädel
In: Schinz, Frommhold W, Hrsg.
Radiologische Diagnostik in Klinik und Praxis. Band 6.
Stuttgart Thieme, 1986:52-60.
49. Gamburg ES, Regine WF, Patchell RA; et al.
The prognostic significance of midline shift at presentation on survival in patients with glioblastoma multiforme.
Int J Radiat Oncol Biol Phys 2000;48(5):1359-62.
50. Garden AS, Maor MH, Yung WK, et al.
Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas.
Radiother Oncol 1991;20:99-110.
51. Giles GG, Thursfield V, Staples M, et al.
Incidence and Survival from Childhood Cancers in Victoria 1970-79 and 1980-89.
Melbourne: Anti Cancer Council of Victoria, 1993
52. Glantz M, Hoffmann J, Coleman R.
Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
Ann Neurol 1991;29:347.
53. Glantz MJ, Burger PC, Herndon II JE, et al.
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas.
Neurology 1991;41:1741-4.
54. Golgi C.
Über die Gliome des Gehirns
(Untersuchungen über den feineren Bau des Nervensystems)
Jena Fischer, 1884.

55. Graif MR, Steiner RE.
Contrast-enhanced magnetic resonance imaging of tumors of the central nervous system: a clinical review.
Brit Radiol 1986;.59:865-73.
56. Grieg NH, Ries LG, Yancik R, et al.
Increasing annual incidence of malignant brain tumors in the elderly.
J Natl Cancer Inst 1990;82:1621-4.
57. Grieg NH.
Brain tumors and the blood-brain barrier.
In: Neuwelt EA, ed. Implications of the Blood-brain Barrier and its Manipulation.
New York Plenum Press, 1989:77-106.
58. Gross MW, Engenhardt-Cabilic R.
Kombinierte Radio-/Chemotherapie mit Topotecan.
Strahlenther Onkol 1999;175:191.
59. Halligan JB, Stelzer KJ, Rostomily RC, et al.
Operation and permanent low activity ¹²⁵I brachytherapy for recurrent high-grade astrocytomas.
Int J Radiat Oncol Biol Phys 1996;35(3):541-7.
60. Halperin EC, Bentel G, Heinz ER, et al.
Radiation therapy treatment planning in supratentorial glioblastoma multiforme: Analysis based on post mortem topographic anatomy with CT correlations.
Int J Radiat Oncol Biol Phys 1989;17:1347-50.
61. Halperin EC, Herndon J, Schold SC, et al.
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium.
Int J Radiat Oncol Biol Phys 1996;34(4):793-802.
62. Hammoud MA, Sawaya R, Shi W, et al.
Prognostic significance of preoperative MRI scans in glioblastoma multiforme.
J Neuro Oncol 1996;27:65-73.
63. Hardell L, Naman A, Pahlson A, et al.
Use of cellular telephones and the risk for brain tumors: a case-control study.
Int J Oncol 1999;15(1):113-6.

64. Hartmann M, Jansen O, Egelhof T, et al.
Einfluß des Hirnödems auf das Rezidivwachstum maligner Gliome.
Radiologe 1998;38:948-53.
65. Henn W, Urbschat S.
Genetische Grundlagen der Entstehung von Hirntumoren.
Radiologe 1998;38:898-903.
66. Hess CF, Schaaf JC, Kortmann RD, et al.
Malignant glioma: patterns of failure following individually tailored limited volume irradiation.
Radiother Oncol 1994;30(2):146-9.
67. Hess KR.
Extent of resection as a prognostic variable in the treatment of gliomas.
J Neuro-Oncol 1999;42:227-31.
68. Heuser K.
Chemotherapie bei malignen Gliomen.
Neurochirurgica 1990;33 Suppl1:20-2.
69. Hicks RJ, Hesselink JR, Wismaer GL, et al.
Brain: Neoplasia.
In: Edelman R, Hesselink JR, eds. Clinical Magnetic Resonance Imaging.
Philadelphia W.B.Saunders, 1990:483-515.
70. Hildebrand J, Sahmoud T, Mignolet F, et al.
Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. EORTC Brain Tumor Group.
Neurology 1994;44(8):1479-83.
71. Hilton DA, Penney M, Pobereskin L, et al.
Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival.
Histopathology 2004;44(6):555-60.
72. Hinkelbein W, Bruggmoser G, Schmidt M, et al.
Kurzzeitbestrahlung des Glioblastoms mit hohen Einzeldosen.
Strahlentherapie 1984;160:301-8.
73. Hirschfelder JO.
Removal of a tumor of the brain.
Pac Med Surg J 1886;29:210-6.

74. Horsley V.
Ten consecutive cases of operations upon the brain and cranial cavity to illustrate details and safety of the method employed.
BMJ 1887;1:863-5.
75. Hulshof MC, Koot RW, Schimmel EC, et al.
Prognostic factors in glioblastoma multiforme.
Strahlenther Onkol 2001;6:283-90.
76. Inskip PD, Tarone RE, Hatch EE, et al.
Cellular-telephone use and brain tumors.
N Engl J Med 2001;344(2):79-86.
77. James CD, Carlom E, Dumanski JP, et al.
Clonal genomic alterations in glioma malignancy stages.
Cancer Res 1988;48(19):5546-51.
78. Jeremic B, Grujicic D, Antunovic V, et al.
Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach.
J Neurooncol 1994;21(2):177-85.
79. Johansen C, Boice JD, McLaughlin JK, et al.
Cellular telephones and cancer-a nationwide cohort study in Denmark.
Journal of the National Cancer Institute 2001;93(3):203-7.
80. Kahn D, Follett KA, Bushnell DL, et al.
Diagnosis of recurrent brain tumor: Value of 201TI SPECT vs 18F-fluorodeoxyglucose PET.
AJR Am J Roentgenol 1994;163(6):1459-65.
81. Kallio M.
Therapy and survival of adult patients with intracranial glioma in a defined population.
Acta Neurol Scand 1990;81:541-9.
82. Kallio M, Sankila R, Jääskeläinen J, et al.
A population-based study on the incidence and survival rates of 3857 glioma patients diagnosed from 1953 to 1984.
Cancer 1991;68:1394-400.

83. Kallwn K, Heiling M, Andersson AM, et al.
Preoperative grading of glioma malignancy with thallium-201 single-photon emission CT: comparison with conventional CT.
AJNR 1996;17(5):925-32.
84. Keles GE, Anderson B, Berger MS, et al.
The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere.
Surg Neurol 1999;52(4):371-9.
85. Kelly PJ, Dumas-Duport C, Kispert DB, et al.
Imaging-based stereotactic serial biopsies in untreated intracranial glial neoplasms.
J Neurosurg 1987;66:865-74.
86. Kernohan JW, Mabon RF, Svien HJ, et al.
A simplified classification of the gliomas.
Proc Staff Meet Mayo Clin 1949;24:71-5.
87. Kleihues P, Cavenee WK.
Pathology and genetics of tumours of the nervous system (WHO).
Published by the International Agency for Research on Cancer
Lyon; IARC Press: 2000
88. Krayenbühl H, Yasargil MG, Huber P.
Zerebrale Angiographie für Klinik und Praxis, 3.Aufl.
Stuttgart Thieme, 1979: 76-80.
89. Kreth FW, Berlis A, Spiropoulou V, et al.
The role of tumor resection in the treatment of glioblastoma multiforme in adults.
Cancer 1999;86(10):2117-23.
90. Kretschmar K, Müller-Forell W.
Kriterien der Malignität bei Hirntumoren im Computertomogramm.
In: Betz H, ed. Hirntumoren.
Konstanz Schnetztor, 1992:91-7.
91. Kyritsis AP, Bondy ML, Xiao M, et al.
Germline p53 gene mutations in subsets of glioma patients.
J Natl Cancer Inst 1994;86:344-9.

92. Lacroix M, Abi-Said D, Fourney R, et al.
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
J Neurosurg 2001;95:190-8.
93. Lai DM, Lin SM, Tu YK, et al.
Therapy for supratentorial malignant astrocytomas: survival and possible prognostic factors.
J Formos Med Assoc 1993;92(3):220-6.
94. Laws ER Jr.
Central Nervous System Tumors: What Have We Learned and Where Are We Heading?
CA Cancer J Clin 1998;48:327-9.
95. Laws ER Jr, Thapar K.
Brain tumors.
CA Cancer J Clin 1993;43:263-71.
96. Laws ER, Parney IF, Huang W, et al.
Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project.
J Neurosurg 2003;99:467-73.
97. Leibel SA, Gutin PH, Wara WM, et al.
Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas.
Int J Radiat Oncol Biol Phys 1989;17(6):1129-39.
98. Lev MH, Rosen BR.
Clinical applications of intracranial perfusion MR imaging.
Neuroimaging Clin N Am 1999;9(2):309-31.
99. Levivier M, Goldman S, Pirotte B, et al.
Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose.
J Neurosurg 1995;82:445-52.
100. Li FP, Fraumeni JF Jr.
Prospective study of a family cancer syndrome.
JAMA 1982;247(19):2692-4.

101. Lutterbach J, Bertelt S, Momm F, et al.
Is older age associated with a worse prognosis due to different patterns of care? A long term study of 1346 patients with glioblastoma or brain metastasis.
Cancer 2005;103(6):1234-44.
102. Lutterbach J, Sauerbrei W, Guttenberger R.
Multivariate Analysis of Prognostic Factors in Patients with Glioblastoma.
Strahlentherapie und Onkologie 2003;179(1):8-15.
103. Lynch HT, Krush AJ, Harlan WL, et al.
Association of soft tissue sarcoma, leukemia, and brain tumors in families affected with breast cancer.
Am Surg 1973;39(4):199-206.
104. Mahaley MS.
Neuro-oncology index and review (adult primary brain tumors).
J Neuro-Oncol 1991;11:85-147.
105. Mahaley MS Jr, Mettlin C, Natarajan N, et al.
National survey of patterns of care for brain-tumor patients.
J Neurosurg 1989;71(6):826-36.
106. Maldaun MV, Suki D, Lang FF, et al.
Cystic glioblastoma multiforme: survival outcomes in 22 cases.
J Neurosurg 2004;100(1):61-7.
107. Mao Y, Desmeules MR, Semenciw R, et al.
Increasing brain cancer rates in Canada.
Can Med Assoc J 1991;145:1583-91.
108. Margetts JC, Kalyan-Raman UP.
Giant-celled glioblastoma of brain. A clinico-pathological and radiological study of ten cases (including immunohistochemistry and ultrastructure).
Cancer 1989;63(3):524-31.
109. Matson GB, Weiner MW.
Spectroscopy.
In: Stark DD, Bradley WG Jr, eds. Magnetic resonance imaging, 3rd ed.
St.Louis Mosby-Year Book, 1999:181-214.

110. McKeran RO, Thomas DGT.
The clinical study of gliomas.
In: Thomas DGT, Graham DI, eds.
Brain Tumors: Scientific basis, clinical investigation and current therapy.
London Butterworth, 1980:194-230.
111. Mehta MP, Masciopinto J, Rozental J, et al.
Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage.
Int J Radiat Oncol Biol Phys 1994;30(3):541-9.
112. Mironov A.
Hirntumoren im cerebralen Angiogramm
In: Betz H, Hrsg. Hirntumoren
Konstanz Schnetztor, 1992:112-3.
113. Moertel CG, Dockerty MB, Baggenstoss AH.
Multiple Primary Malignant Neoplasms.
Cancer 1961;14:238.
114. Müller W, Afra D, Schröder R.
Supratentorial recurrences of gliomas. Morphological studies in relation to time intervals with astrocytomas.
Acta Neurochir 1977;37(1-2):75-91.
115. Muscat JE, Malkin MG, Thompson S, et al.
Handheld cellular telephone use and risk of brain cancer.
JAMA 2000;284(23):3001-7.
116. Myint PK, May HM, Baillie-Johnson H, et al.
CT diagnosis and outcome of primary brain tumours in the elderly: a cohort study.
Gerontology 2004;50(4):235-41.
117. Nafe R, Franz K, Schlote W, et al.
Morphology of Tumor Cell Nuclei Is Significantly Related with Survival Time of Patients with Glioblastomas.
Clin Cancer Res 2005;11:2141-48.
118. Nelson JS, Tsukada Y, Schoenfeld D, et al.
Necrosis as a prognostic criterion in malignant supratentoriell astrocytic gliomas.
Cancer 1983;52:550-4.

119. NOA
Leitlinie Diagnostik und Therapie der Gliome des Erwachsenenalters.
München Zuckschwerdt, 2004
120. Oertel J, von Buttlar E, Schroeder HWS, Gaab MR.
Prognosis of gliomas in the 1970s and today.
Neurosurg Focus 2005;18(4):12.
121. Ohnishi T, Arita N, Hayakawa T, et al.
Motility factor produced by malignant glioma cells: role of tumor invasion.
J Neurosurg 1990;73:881-8.
122. Ostertag CB, Mennel HD, Kiessling M.
Stereotactic biopsy of brain tumors.
Surg Neurol 1980;14(4):275-83.
123. Parsa AT, Wachhorst S, Lamborn KR, et al.
Prognostic significance of intracranial dissemination of glioblastoma
multiforme in adults.
J Neurosurg 2005;102(4):622-8.
124. Patel S, Breneman JC, Warnick RE, et al.
Permanent iodine-125 interstitial implants for the treatment of recurrent
glioblastoma multiforme.
Neurosurgery 2000;46(5):1123-8.
125. Penman J, Smith MS.
Intracranial gliomata.
Spec Rep Ser med Res Coun 1954;284:1-69.
126. Pierallini A, Bonamini M, Pantano P, et al.
Radiological assessment of necrosis in glioblastoma:
variability and prognostic value.
Neuroradiology 1998;40:150-3.
127. Pilkington GJ.
Tumour cell migration in the central nervous system.
Brain Pathol 1994;4:157-66.
128. Pilkington GJ.
The paradox of neoplastic glial cell invasion of the brain and apparent
metastatic failure.
Anticancer Res 1997;17(68):4103-5.

129. Pope WB, Sayre J, Perlina A, et al.
MR Imaging Correlates of Survival in Patients with High-Grade Gliomas
AJNR 2005;26:2466-74.
130. Prados MD, Gutin PH, Phillips TL, et al.
Interstitial brachytherapy for newly diagnosed patients with malignant gliomas:
the UCSF experience.
Int J Radiat Oncol Biol Phys 1992;24(4):593-7.
131. Proescholdt MA, Heiss JD, Walbridge S, et al.
Vascular endothelial growth factor (VEGF) modulates vascular permeability
and inflammation in rat brain.
J Neuropathol Exp Neurol 1999;58:613-27.
132. Proescholdt MA, Macher C, Woertgen C, et al.
Level of evidence in the literature concerning brain tumor resection.
Clin Neurol Neurosurg 2005;107(2):95-8.
133. Radhahrishnan K, Bohnen NI, Kurland LT.
Epidemiology of brain tumors.
In: Morantz RA, Walsh JW, eds. Brain tumors.
New York Dekker, 1994:1-19.
134. Reeves RI, Marks JE.
Prognostic significance of lesion size for glioblastoma multiforme.
Radiology 1979;132:469-71.
135. Riggs JE.
Longitudinal Gompertzian analysis of primary malignant brain tumor mortality
in the U.S., 1962-1987: Rising mortality in the elderly is the natural
consequence of competitive deterministic dynamics.
Mech Ageing Devel 1991;60:225-41.
136. Salcman M.
Survival in glioblastoma: historical perspective.
Neurosurgery 1980;7:435-9.
137. Salcman M.
Epidemiology and factors affecting survival.
In: Apuzzo MLJ, ed. Malignant Cerebral Glioma.
Park Ridge American Association of Neurological Surgeons, 1990:95-109.

138. Salcman M.
Intracranial hemorrhage caused by brain tumor.
In: Kaufmann HH, ed. Intracerebral Hematomas.
New York Raven Press, 1992:95-106.
139. Salcman M.
Intrinsic cerebral glioma.
In: Apuzzo MLJ, ed. Brain surgery, Complication Avoidance and Management.
New York Churchill Livingstone, 1993:379-90.
140. Salcman M.
Glioblastoma multiforme and anaplastic astrocytoma
In: Kaye AH, Laws ER Jr, ed. Brain Tumors
London Churchill Livingstone, 2001:493-523.
141. Salcman M, Broadwell RD.
The blood-brain barrier.
In: Salcman M, ed. Neurobiology of Brain Tumors. Vol.4.
Baltimore William and Wilkins, 1991:229-49.
142. Salcman M, Scholtz H, Kaplan RS.
Long-term survival in patients with malignant astrocytoma.
Neurosurgery 1994;34:213-20.
143. Salminen E, Nuutien JM, Huhtala S.
Multivariate analysis of prognostic factors in 106 patients with malignant glioma.
Eur J Cancer 1996;32A:1918-23.
144. Sarkaria JN, Mehta MP, Loeffler JS, et al.
Radiosurgery in the initial management of malignant gliomas: survival comparison
with the RTOG recursive partitioning analysis.
Radiation Therapy Oncology Group.
Int J Radiat Oncol Biol Phys 1995;32(4):931-41.
145. Sartor K.
Magnetresonanztomographie (MRT) bei Hirntumoren.
In: Betz H, ed. Hirntumoren.
Konstanz Schnetztor, 1992:98-111.
146. Sawaya R.
Extent of resection in malignant gliomas: a critical summary.
J Neurooncol 1999;42:303-5.

147. Sawaya R, Yamamoto M, Ramo J, et al.
Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis.
Neurosurgery 1995;36:375-80.
148. Scharfen CO, Sneed PK, Wara WM, et al.
High activity iodine-125 interstitial implant for gliomas.
Int J Radiat Oncol Biol Phys 1992;24(4):583-91.
149. Schlegel U.
Klinische Symptomatik und allgemeine Therapie - epileptische Anfälle.
In: Schlegel U, Weller M, Westphal M, Hrsg. Neuroonkologie
Stuttgart Thieme, 2003:93-7.
150. Schoenberg BS.
Epidemiology of primary intracranial neoplasms:
disease distribution and risk factors.
In: Salzman M, ed. Neurobiology of Brain Tumors.
Baltimore Williams and Wilkins, 1991:3-18.
151. Schröder JM.
Zerebrale raumfordernde Prozesse.
In: Hopf HCh, Poeck K, Schliack H, Hrsg. Neurologie in Praxis und Klinik. 2.Aufl.
Stuttgart Thieme, 1992:324-39.
152. Schwartz RB.
Functional imaging of brain tumors.
In: Black P McL, Loeffler JS, eds. Cancer of the Nervous System.
Cambridge Blackwell Science, 1997:106-27.
153. Scott JN, Brasher PM, Sevick RJ, et al.
How often are nonenhancing supratentorial gliomas malignant?
Neurology 2002;59(6):947-9.
154. Segall HD, Destian S, Nelson MD, et al.
CT and MR imaging in malignant gliomas.
In: Apuzzo MLJ, ed. Malignant Cerebral Glioma.
Park Ridge American Association of Neurologic Surgeons, 1990:63-78.

155. Seifert V.
Neurochirurgische Therapie der malignen Gliome.
In: Böttcher HD, Seifert V, Henke M, et al, Hrsg.
Klinik der hirneigenen Tumoren und Metastasen.
München Zuckschwerdt, 2002:96-102.
156. Selikoff IJ
The investigation of brain tumor occurrence in other occupational
groups: introduction.
Ann N Y Acad Sci 1982;381:116-8.
157. Shah GD, Kesari S, Xu R, et al.
Comparison of linear and volumetric criteria in assessing tumor response
in adult high-grade gliomas.
Neuro Oncol 2006;8(1):38-46.
158. Shapiro WR, Green SB, Burger PC, et al.
Randomized trial of three chemotherapy regimens and two radiotherapy regimens
in postoperative treatment of malignant glioma:
Brain Tumor Cooperative Group Trial 8001.
J Neurosurg 1989;71:1-9.
159. Sheline GE, Wara WM, Smith V.
Therapeutic irradiation and brain injury.
Int J Radiat Oncol Biol Phys 1980;6:1215-28.
160. Shibamoto Y, Yamashita J, Takahashi M, et al.
Supratentoriell malignant glioma: An analysis of radiation therapy in 178 cases.
Radiother Oncol 1990;18:9-17.
161. Simpson JR, Horton J, Scott C, et al.
Influence of location and extent of surgical resection on survival of patients
with glioblastoma multiforme: results of three consecutive
Radiation Therapy Oncology Group (RTOG) clinical trials.
Int J Radiat Oncol Biol Phys 1993;26(2):239-44.
162. Stark AA, Bradley WG.
Magnetic Resonance Imaging, 3rd ed.
St.Louis Mosby, 1999,39-72.

163. Stewart LA.
Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.
Lancet 2002;359:1011-8.
164. Stewart PA, Hyakawa K, Farrell CL, et al.
Quantitative study of microvessel ultrastructure in human peritumoral brain tissue: Evidence for a blood-brain barrier defect.
J Neurosurg 1987;67:697-705.
165. Stupp R, Dietrich PY, Ostermann F, Kraljevic S, et al.
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
J Clin Oncol 2002;20(5):1375-82.
166. Stupp R, Mason WP, van den Bent MJ, et al.
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N Engl J Med 2005;352(10):987-96.
167. Sze G, Berry I, Brant-Zawadzki M, et al.
Gadolinium DPTA in the magnetic resonance evaluation of the postoperative patient. Work in progress.
Acta Radiol 1982;369:368-71.
168. Takamura Y, Ibayashi Y, Morimoto S, et al.
Clinical analysis of the fatal cases of adult malignant gliomas after aggressive treatment.
No Shinkei Geka 1994;22(3):207-13.
169. Tohma Y, Gratas C, Biernat W, et al.
PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
J Neuropathol Exp Neurol 1998;57(7):684-9.
170. Traber F, Block W, Flacke S, et al.
1H-MR Spectroscopy of brain tumors in the course of radiation therapy: Use of fast spectroscopic imaging and single-voxel spectroscopy for diagnosing recurrence.
RöFo 2002;174:33-42.

171. Trouillas P, Menaud G, DeThe G, et al.
Etude epidemiologique des tumeurs primitives du neuraxe dans
la region Rhone-Alpes.
Rev Neurol 1975;131:691-708.
173. Urbach H, Solymosi L.
Diagnostik
In: Schlegel U, Weller M, Westphal M, Hrsg. Neuroonkologie. 2.Aufl.
Stuttgart Thieme, 2003:55-61.
174. Vertosick FT Jr, Selker GR.
Brain stem and spinal metastases of supratentorial glioblastoma multiforme:
a clinical series.
Neurosurgery 1990;27:516-22.
175. Virchow R.
Die Cellularpathologie in ihrer Begründung auf physiologische und
pathologische Gewebelehre.
Berlin Hirschwald, 1858
176. Virchow R.
Die krankhaften Geschwülste.
Berlin Hirschwald, 1863
177. Vogl G, Grodd W, Voigt K.
Der Hirntumor mit i.v. Kontrastmittel im CT
In: Betz H, Hrsg. Hirntumoren
Konstanz Schnetztor, 1992:123.
178. Vorster SJ, Barnett GH.
A proposed preoperative grading scheme to assess risk for surgical resection
of primary and secondary intraaxial supratentoriell brain tumors.
Neurosurg Focus 1998;4(6):2
179. Walker AE, Robins M, Weinfeld FD.
Epidemiology of brain tumors: the national survey of intracranial neoplasms.
Neurology 1985;35:219-26.
180. Walker MD.
The contemporary role of chemotherapy in the treatment of malignant
brain tumor.
Clin Neurosurg 1978;25:388-96.

181. Walker MD, Alexander E, Hunt WE, et al.
Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas.
J Neurosurg 1978;49:333-43.
182. Walker MD, Green SB, Byar DP.
Randomized comparisons of radiotherapy and nitrosoureas for treatment of malignant glioma and surgery.
N Engl J Med 1980;303:1323-9.
183. Wallner KE, Galicich JH, Krol G.
Patterns of failure following treatment for glioblastoma multiforme.
Int J Radiat Oncol Biol Phys 1989;16:1405-9.
184. Wang YY, Yang GK, Li SY, et al.
Prognostic factors for deep situated malignant gliomas treated with linac radiosurgery.
Chin Med Sci J 2004;19(2):105-10.
185. Warren KE, Patronas N, Aikin AA, et al.
Comparison of one-, two- and three-dimensional measurements of childhood brain tumors.
J Natl Cancer Inst 2001;93(18):1401-5.
186. Weiner IM
Diuretics and other agents employed in the mobilization of edema fluid.
In: Goodman and Gilman`s: The Pharmacological Basis of Therapeutics. 8th ed.
New York McGraw-Hill, 1992:714-5.
187. Weissenberger J, Steinbach JP, Malin G, et al.
Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
Oncogene 1997;14(17):2005-13.
188. Weller M.
Leitlinie "Maligne Gliome" der Deutschen Gesellschaft für Neurologie.
Informationszentrum für Standards in der Onkologie (ISTO)
der Deutschen Krebsgesellschaft, Frankfurt am Main 2003
189. Weller M, Westphal M.
Glioblastom.
In: Schlegel U, Weller M, Westphal M, Hrsg. Neuroonkologie
Stuttgart Thieme, 2003:196-204.

190. Weller M, Westphal M.
Grundlagen der speziellen Therapie.
In: Schlegel U, Weller M, Westphal M, Hrsg. Neuroonkologie
Stuttgart Thieme, 2003:123.
191. Westphal M, Hilt D, Bortey E, et al.
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU)
wafers (Gliadel wafers) in patients with primary malignant glioma.
Neuro Oncology 2003;5:6-15.
192. Westphal M, Winking M.
Klinische Symptomatik und allgemeine Therapie - Intrakraniale Druckerhöhung.
In: Schlegel U, Weller M, Westphal M, Hrsg. Neuroonkologie
Stuttgart Thieme, 2003:86-92.
193. Wiestler OD, Becker A, Burkhardt K, et al.
Pathologie und biologische Grundlagen hirneigener Tumoren.
In: Böttcher HD, Seifert V, Henke M, Mose St, Hrsg.
Klinik der hirneigenen Tumoren und Metastasen,
Grundlagen-Diagnostik-Therapie.
München Zuckschwerdt, 2002:1-21.
194. Wilcke O.
Infratentorielle Tumoren.
In: Dietz H, Umbach W, Wüllenweber R, Hrsg.
Klinische Neurochirurgie, Bd.2. Klinik und Therapie
Stuttgart Thieme, 1984:245.
195. Wilkowski R, Zimmermann F.
Supportive Maßnahmen in der Strahlentherapie.
In: Manual Supportive Maßnahmen und symptomorientierte Therapie
in der Hämatologie und Onkologie-Tumorzentrum München
München Zuckschwerdt, 2001:140-7.
196. Winger MJ, Macdonald DR, Schold SC, et al.
Selection bias in clinical trials of anaplastic glioma.
Ann Neurol 1989;26:531-4.

197. Wirtz CR, Albert FK, Schwaderer M, et al.
The benefit of neuronavigation for neurosurgery analyzed by impact on glioblastom surgery.
Neurol Res 2000;22:354-60.
198. Wong ET, Hess KR, Gleason MJ, et al.
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials:
J Clin Oncol 1999;17:2572-8.
199. Wood JR, Green SB, Shapiro WR.
The prognostic importance of tumor size in malignant gliomas:
a computed tomographic scan study by the Brain Tumor Cooperative Group.
J Clin Oncol 1988;6(2):338-43.
200. Wüllenweber R, Wassmann H.
Raumfordernde Prozesse der Großhirnhemisphären
In: Hopf HCh, Poeck K, Schliack H, Hrsg.
Neurologie in Praxis und Klinik. 2.Auflage.
Stuttgart Thieme, 1992:7.14-7.23.
201. Yamada K, Ushio Y, Hayakawa T.
Effects of steroids on the blood brain barrier.
In: Neuwelt EA, ed. Implications of the Blood-brain Barrier and its Manipulation.
New York Plenum Press, 1989:53-76.
202. Yu ZY, Wrange O, Boethiers J, et al.
A study of glucocorticoid receptors in intracranial tumors.
J Neurosurg 1981;55:757-60.
203. Zeidler U, Kottke S, Hundeshagen H.
Hirnszintigraphie, 2.Aufl.
Berlin Springer, 1975:29-33.
204. Zuccaro G, Taratuto AL, Monges J.
Intracranial neoplasms during the first year of life.
Surg Neurol 1986;26(1):29-36.
205. Zülch KJ.
Biologie und Pathologie der Hirngeschwülste.
In: Krenkel W, Olivecrona H, Tönnis W. Handbuch der Neurochirurgie. Bd.III.
Berlin Springer, 1956:49.

206. Zülch KJ.

Histological typing of tumours of the central nervous system
(Internat Histol Classific of Tumours. No21).

Geneva World Health Organisation, 1979